+17.2%
XLI vs MRNA
+511.3%
-494.1%
-12.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.4% | -2.2% | +2.6% | +0.4% |
| 7D | -1.1% | +5.5% | -6.5% | -1.1% |
| 30D | -5.9% | +158.7% | -164.7% | -7.5% |
| 3M | -0.3% | +182.1% | -182.4% | -3.4% |
| 6M | +0.1% | +151.8% | -151.7% | -2.5% |
| YTD | +13.6% | +393.6% | -380.0% | +4.7% |
| 1Y | +17.2% | +499.5% | -482.3% | +6.3% |
| All | +17.2% | +511.3% | -494.1% | +6.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling